Wedbush analyst Robert Driscoll downgraded Surface Oncology (SURF) to Neutral from Outperform after it was announced that Coherus Biosciences (CHRS) will acquire Surface in a stock-for-stock transaction.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SURF: